CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum

scientific article

CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1471-4159.2006.04383.X
P698PubMed publication ID17250681
P5875ResearchGate publication ID6552362

P2093author name stringDavid A Price
Alan Frazer
James L Roberts
Andrea Giuffrida
Lynette C Daws
William A Owens
Georgianna G Gould
P2860cites workDifferences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.Q46567318
Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouseQ46744003
Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitroQ48127886
Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake ratsQ48547114
Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study.Q51976878
Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain.Q52030475
A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing.Q52186778
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporterQ24310836
Marijuana and cannabinoid regulation of brain reward circuitsQ24671514
Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neuronsQ28272251
In silico patent searching reveals a new cannabinoid receptorQ28284495
Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulataQ28377147
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brainQ31570267
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?Q33211909
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigraQ34421920
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.Q34602111
Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious ratsQ35041427
Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptorQ35048967
Rapid regulation of the dopamine transporter: role in stimulant addiction?Q35908701
[3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer compositionQ38312510
Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporterQ40623607
Dopamine activation of endogenous cannabinoid signaling in dorsal striatumQ41646203
The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.Q42450193
Nigrostriatal dopamine release modulated by mesopontine muscarinic receptorsQ42464758
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's diseaseQ43504648
Effects of recording media composition on the responses of Nafion-coated carbon fiber microelectrodes measured using high-speed chronoamperometry.Q43698340
Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouseQ44084440
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanismQ44346123
Individual differences in cocaine-induced locomotor sensitization in low and high cocaine locomotor-responding rats are associated with differential inhibition of dopamine clearance in nucleus accumbensQ44370408
Chloral hydrate and ethanol, but not urethane, alter the clearance of exogenous dopamine recorded by chronoamperometry in striatum of unrestrained ratsQ44443006
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.Q44885114
Role of the dopamine transporter in the differential cocaine-induced locomotor activation of inbred long-sleep and short-sleep miceQ44938350
Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex--involvement of Na(+)/K(+)-ATPaseQ44946148
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonismQ45310537
Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometryQ46373381
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.Q46384445
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectdopamineQ170304
cannabinoidsQ422936
striatumQ1319792
P1104number of pages8
P304page(s)389-396
P577publication date2007-01-23
P1433published inJournal of NeurochemistryQ6295643
P1476titleCB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum
P478volume101

Reverse relations

cites work (P2860)
Q42087548A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
Q37200559Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder
Q37752096Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas
Q34899462Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.
Q38522769Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia
Q36157657Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?
Q38207680Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions
Q37039010Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol
Q33996977Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels
Q34543977Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration
Q37132571Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2
Q36074595New insights on endocannabinoid transmission in psychomotor disorders
Q34302209Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms
Q35499568Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection
Q38616780Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice.
Q34540543Regulation of monoamine transporters: Role of transporter phosphorylation
Q35848200Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism
Q34181090The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.
Q90623137The role of CA1 CB1 receptors on lithium-induced spatial memory impairment in rats
Q37371387WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Search more.